Evidence map›Paper›PMID 41797920›Full record

ArticleiScience2026

Immunotherapy rechallenge after progression in non-small cell lung cancer: A systematic review and network meta-analysis.

Ying Li, Junfeng Zhao, Jiaxuan Chen, Chen Zhou, Yifei Yan, Wenjie Chen, Yali Xu, Yintao Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ying LiDepartment of Respiratory Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250000, China.
Junfeng ZhaoDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250000, China.
Jiaxuan ChenShandong First Medical University, and Shandong Academy of Medical Sciences, Jinan, Shandong 250000, China.
Chen ZhouShandong First Medical University, and Shandong Academy of Medical Sciences, Jinan, Shandong 250000, China.
Yifei YanShandong First Medical University, and Shandong Academy of Medical Sciences, Jinan, Shandong 250000, China.
Wenjie ChenShandong First Medical University, and Shandong Academy of Medical Sciences, Jinan, Shandong 250000, China.
Yali XuDepartment of Pathology, Shandong Provincial Hospital Affiliated with Shandong First Medical University, Jinan, Shandong 250000, China.
Yintao LiDepartment of Respiratory Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To determine whether immunotherapy can be continued in patients with advanced non-small cell lung cancer (NSCLC) after initial immunotherapy. This study aimed to explore whether patients could benefit from immunotherapy after progression and identify the optimal treatment regimen. The included studies were classified into two groups based on whether patients continued immunotherapy rechallenge after disease progression: the immunotherapy rechallenge group and the non-immunotherapy group. The progression-free survival (PFS) and overall survival (OS) of patients in both groups were analyzed. Patients in the immunotherapy rechallenge group showed a significant advantage in PFS (HR: 0.65,

Indexed as

health sciencesmedical specialtymedicineoncology

Identifiers

PMID41797920
PMCPMC12964238

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.